Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

2021480 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 22, Issue 4, pp. 499-511

Field-Weighted Citation Impact: 34.77